Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP263934.RA8ZQIdThN81LrYbkPn2RAtitk1QpLgh8EBVMCjn0LUcM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP263934.RA8ZQIdThN81LrYbkPn2RAtitk1QpLgh8EBVMCjn0LUcM130_assertion type Assertion NP263934.RA8ZQIdThN81LrYbkPn2RAtitk1QpLgh8EBVMCjn0LUcM130_head.
- NP263934.RA8ZQIdThN81LrYbkPn2RAtitk1QpLgh8EBVMCjn0LUcM130_assertion description "[In A375 xenografts, the antitumor effects of sorafenib and MI-319 were additive and associated with the down modulation of Bcl-2 and Bcl-xL, the nuclear translocation of AIF, and increased suppression of tumor angiogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP263934.RA8ZQIdThN81LrYbkPn2RAtitk1QpLgh8EBVMCjn0LUcM130_provenance.
- NP263934.RA8ZQIdThN81LrYbkPn2RAtitk1QpLgh8EBVMCjn0LUcM130_assertion evidence source_evidence_literature NP263934.RA8ZQIdThN81LrYbkPn2RAtitk1QpLgh8EBVMCjn0LUcM130_provenance.
- NP263934.RA8ZQIdThN81LrYbkPn2RAtitk1QpLgh8EBVMCjn0LUcM130_assertion SIO_000772 21929745 NP263934.RA8ZQIdThN81LrYbkPn2RAtitk1QpLgh8EBVMCjn0LUcM130_provenance.
- NP263934.RA8ZQIdThN81LrYbkPn2RAtitk1QpLgh8EBVMCjn0LUcM130_assertion wasDerivedFrom befree-20150227 NP263934.RA8ZQIdThN81LrYbkPn2RAtitk1QpLgh8EBVMCjn0LUcM130_provenance.
- NP263934.RA8ZQIdThN81LrYbkPn2RAtitk1QpLgh8EBVMCjn0LUcM130_assertion wasGeneratedBy ECO_0000203 NP263934.RA8ZQIdThN81LrYbkPn2RAtitk1QpLgh8EBVMCjn0LUcM130_provenance.